Cat# : THP-0102
|THP-0102||Belatacept, Recombinant human CTLA4 protein, Fc tagged||April 02, 2023||5mg||$1,000||
|Add to Cart Online Order Request a Bulk Order|
|Product Name:||Belatacept, Recombinant human CTLA4 protein, Fc tagged|
|Description:||The product is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, the product is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each. It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes.|
|Molecular Weight:||92300.0 Da (with glycosylation)|
|Purity:||>99% by SDS-Page and HPLC analysis|
|Endotoxin Level:||<0.001 EU per 1 μg by the LAL method|
|Applications:||For prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.|
|Examples of Clinical Use:||Organ rejection|
|Pharmacodynamics:||The product binds to CD86 with a 4-fold higher affinity. It also binds to CD80 with a 2-fold higher affinity. It was observed in non-human primates that product prolongs graft survival due to a decrease in antibody production against the donor organ. Furthermore, the product also inhibits the primary humoral immune response which is indicated by the decrease in post-transplant levels of IgG, IgM, and IgA. The magnitude of this effect is more significant than it is in cyclosporine.|
|Mechanism of action:||Belatacept is a fusion protein in which the Fc portion of human IgG1 is attached onto the extracellular portion of human CTLA-4 (CD152). Belatacept specifically binds to CD80 and CD86 receptors that are found on the antigen-presenting cell (B cells, macrophages, dendritic cells) to block selective T-cell lymphocyte costimulation. CD80 and CD86 would normally act as the ligands to the CD28 receptor T-cells in which this interaction triggers the activation of T lymphocytes. However in the presence of belatacept, because the extracellular CTLA-4 component binds to CD28 with higher affinity than CD80 or CD86, T lymphyocyte anergy, a state of antigen specific tolerance, occurs instead. The T cell is also no longer able to respond to their antigen.|
|Affected organisms:||Humans and other mammals|
|Targets:||Target 1. T-lymphocyte activation antigen CD86; Target 2. T-lymphocyte activation antigen CD80|
For more information on how our products could help advance your project, please contact us.
ENTER YOUR EMAIL HERE TO SUBSCRIBE.
Copyright © Creative BioMart. All Rights Reserved.